# Regorafenib Alone or in Combined With Transcatheter Arterial ChEmoembolization in Treatment of Advanced Hepatocellular Carcinoma After First Line Targeted Therapy

> **NCT05811481** · — · UNKNOWN · sponsor: **WenBo Guo** · enrollment: 192 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Transcatheter Arterial ChEmoembolization
- Regorafenib

## Interventions

- **PROCEDURE:** TACE
- **DRUG:** Regorafenib

## Key facts

- **NCT ID:** NCT05811481
- **Lead sponsor:** WenBo Guo
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12-27
- **Primary completion:** 2024-12-27
- **Final completion:** 2025-12-27
- **Target enrollment:** 192 (ESTIMATED)
- **Last updated:** 2023-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05811481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05811481, "Regorafenib Alone or in Combined With Transcatheter Arterial ChEmoembolization in Treatment of Advanced Hepatocellular Carcinoma After First Line Targeted Therapy". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05811481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*